Learn more about whether SoundHound AI, Inc. or Vertex, Inc. is a better investment based on AAII's A+ Investor grades, which ...

According to Benzinga Pro, Vertex Pharmaceuticals's peer group average for short interest as a percentage of float is 6.62%, ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex ...

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 2.92% to $485.89 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 2.24% to ...

Morgan Stanley lowered the firm’s price target on Vertex (VERX) to $55 from $60 and keeps an Overweight rating on the shares. The firm is ...

In a report released today, Chris Quintero from Morgan Stanley maintained a Buy rating on Vertex (VERX – Research Report), with a price target ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $51.3, a high estimate of $61.00, and a low estimate of $31.00. A 14.64% drop is evident in the current ...

As the U.S. stock market grapples with volatility driven ... In this article, we are going to take a look at where Vertex, Inc. (NASDAQ:VERX) stands against the other software stocks.

Shares of Vertex have rallied, even amid the broader stock market sell-off. The company is diversifying beyond its dominance in cystic fibrosis treatments. Several catalysts in 2025 support a ...